FDA Awards $1M to Phase 2 Study of Ifetroban in Treating Heart Disease Linked to Duchenne MD
Cumberland Pharmaceuticals announced that it has been awarded a $1 million grant by the U.S. Food and Drug Administration (FDA) to support a Phase 2 clinical trial into oral ifetroban as potential treatment of heart disease associated with Duchenne muscular dystrophy (DMD). The award marks the first time…